Immunologic Factor – Page 27

Alhemo: A Breakthrough in Hemophilia Treatment – FDA Approves Novo Nordisk’s Once-Daily Prophylactic Injection for Hemophilia A and B with Inhibitors

9 months ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A and B, inhibitors, Nordisk, once-daily, Prophylactic treatment, United States Food and Drug Administration

Alhemo, Novo Nordisk, Hemophilia A and B, Inhibitors, FDA Approval, Once-Daily Prophylactic Treatment, Concizumab

GSK Reports Mixed Results for Jemperli/Zejula Combination in First-Line Ovarian Cancer Trial

9 months ago talkbio0Tagged Clinical Trials, first-line, Jemperli, mixed survival data, ovarian neoplasm, SmithKline Beecham, Zejula

GSK, Jemperli, Zejula, ovarian cancer, first-line treatment, mixed survival data, clinical trial results

GSK’s Zejula-Jemperli Combination Achieves Primary Endpoint in Ovarian Cancer Trial, Falls Short on Overall Survival

9 months ago talkbio0Tagged FIRST trial, Jemperli, ovarian neoplasm, Progression-Free Survival, SmithKline Beecham, Survival, Zejula

GSK, Zejula, Jemperli, ovarian cancer, FIRST trial, progression-free survival, overall survival

Regeneron Advances Anticoagulant Antibody Pair to Late-Stage Testing

9 months ago talkbio0Tagged Antibodies, Anticoagulants, late-stage testing, Regeneron, REGN7508, REGN9933

Regeneron, anticoagulant, antibody, late-stage testing, Factor XI, REGN7508, REGN9933

Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends

9 months ago talkbio0Tagged alpha-Synuclein, PADOVA study, Parkinson 's disease, Phase 2b Trial, Prasinezumab, Prothena, Roche (company)

Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study

Narsoplimab Demonstrates Significant Survival Benefit in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

9 months ago talkbio0Tagged disease treatment, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, HSCT-TMA, Improvement, Infrequent, Inhibitor, Lectin, MASP2 protein, human, narsoplimab, Overall Survival, Psychological inhibition

Narsoplimab, Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA), Lectin Pathway Inhibition, MASP-2 Inhibitor, Rare Disease Treatment, Overall Survival Improvement

Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends

9 months ago talkbio0Tagged Clinical Trials, exploration, Failure (biologic function), Parkinson 's disease, Prasinezumab, Roche (company), trends qualifier

Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration

Regeneron’s EYLEA HD Succeeds in Phase 3 Trial for Retinal Vein Occlusion, Paving Way for 2025 FDA Submission

9 months ago talkbio0Tagged aflibercept, dosing, Extension, Eylea, Hodgkin Disease, Interval, Phase 3 QUASAR trial, Regeneron, Retinal Vein Occlusion, Submission, United States Food and Drug Administration

EYLEA HD, Aflibercept, Retinal Vein Occlusion (RVO), Phase 3 QUASAR Trial, Extended Dosing Intervals, FDA Submission 2025, Regeneron Pharmaceuticals

FDA Declines Approval for J&J’s Subcutaneous Rybrevant and AstraZeneca’s Full Approval Bid for Andexxa

9 months ago talkbio0Tagged Andexxa, AstraZeneca, J&J, regulatory review, Rybrevant, United States Food and Drug Administration

FDA, J&J, Rybrevant, AstraZeneca, Andexxa, regulatory review, pharmaceuticals

Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results

9 months ago talkbio0Tagged Antibodies, Crohn 's disease, duvakitug, Gastrointestinal Diseases, Immunology, Inflammatory Bowel Diseases, Precision Medicine, TNFSF15 gene, Ulcerative Colitis

Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases